CASI Pharmaceuticals Obtains All Rights And Global Intellectual Property Rights Related To CB-5339 From Cleave Therapeutics; Additionally, CASI Will Assume Responsibility For The US CB-5339 Investigational New Drug Application
Portfolio Pulse from Benzinga Newsdesk
CASI Pharmaceuticals has acquired all rights and global intellectual property rights related to CB-5339 from Cleave Therapeutics. CASI will also assume responsibility for the US CB-5339 Investigational New Drug Application.
July 20, 2023 | 12:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CASI Pharmaceuticals has acquired all rights and global intellectual property rights related to CB-5339 from Cleave Therapeutics. This could potentially lead to new revenue streams for CASI.
The acquisition of all rights and global intellectual property rights related to CB-5339 by CASI Pharmaceuticals from Cleave Therapeutics could potentially lead to new revenue streams for CASI. This is because CASI now has the exclusive rights to develop and commercialize CB-5339, which could result in new products and services. Additionally, CASI will also assume responsibility for the US CB-5339 Investigational New Drug Application, which could potentially lead to regulatory approval and commercialization of the drug in the US.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100